New Stock Listing News | Jiangxi Biology Submits Application to Hong Kong Stock Exchange for the Second Time, the Company is the Largest Provider of Human TAT in China and Worldwide.

According to the disclosure by the Hong Kong Stock Exchange on October 26, Jiangxi Bioproducts Research Institute Co., Ltd. (hereinafter referred to as "Jiangxi Bioproducts") submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and CMSC International as its joint sponsors. The company had previously submitted a listing application to the Hong Kong Stock Exchange on April 11, 2025. According to the prospectus, Jiangxi Bioproducts is China's largest provider and exporter of human tetanus antitoxin ("human TAT") and also a comprehensive serum platform company. Tetanus antitoxin is a serum that provides immediate protection and treatment for tetanus infections by neutralizing the toxin produced by Clostridium tetani (the bacterium that causes tetanus). The company's sales and distribution network covers globally, including a comprehensive distribution network that spans provinces, cities, and counties in China. This network ensures extensive market coverage and efficient delivery to over 23,500 medical institutions (including over 1,500 tertiary medical institutions). According to Frost Sullivan data, the global human serum market increased from $321 million in 2019 to $409 million in 2024, with a compound annual growth rate of 4.9%. It is projected to continue to increase to $821 million by 2028 and reach $2.095 billion by 2033, with compound annual growth rates of 19.1% from 2024 to 2028 and 20.6% from 2028 to 2033. According to Frost Sullivan data, Jiangxi Bioproducts is the largest provider of human TAT in China and globally, with market shares of 65.8% and 36.6% by sales volume in 2024. In 2024, the company's total sales volume of human TAT was 25.4 million units, with 13.2 million units sold in China and 12.2 million units exported to overseas markets. According to Frost Sullivan data, in terms of revenue in 2024, Jiangxi Bioproducts is also the largest provider of human TAT in China, with a market share of 66.8%. The company has maintained a dominant position in the Chinese human TAT market for 18 consecutive years, with a market share of over 50%. During the past performance period, its human TAT was exported to more than 30 countries and regions in Asia and Africa, accounting for nearly 100% of China's exports. According to Frost Sullivan data, based on sales volume in 2024, the company is the largest provider of human TAT in the Philippines and Egypt, with market shares of around 90%. In terms of financials, Jiangxi Bioproducts achieved revenues of approximately RMB 142 million, RMB 198 million, and RMB 221 million in the fiscal years 2022, 2023, and 2024 respectively; with profits of approximately RMB 26.46 million, RMB 55.48 million, and RMB 75.14 million during the same periods.